(HCRU)/Costs and Epidemiology of Patients With ADHD in Germany: A Claims Data Study (HEDDA)
Author(s)
Felix Betzler, PD Dr. med.1, Jana Knop, Dr. rer. nat.2, Martina Grönig, Dr. rer. nat.2, Patrick Timpel, Dr. rer. medic.3, Vukasin Viskovic, NA4, Daniel Schöttle, PD Dr. med.5.
1Charité University Medicine Berlin, Berlin, Germany, 2Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany, 3fbeta GmbH, Berlin, Germany, Berlin, Germany, 4InGef - Institut für angewandte Gesundheitsforschung, Berlin, Germany, 5Asklepios Klinikum Harburg, Hamburg, Germany, Hamburg, Germany.
1Charité University Medicine Berlin, Berlin, Germany, 2Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany, 3fbeta GmbH, Berlin, Germany, Berlin, Germany, 4InGef - Institut für angewandte Gesundheitsforschung, Berlin, Germany, 5Asklepios Klinikum Harburg, Hamburg, Germany, Hamburg, Germany.
OBJECTIVES: This study aimed to assess the prevalence and incidence rates of ADHD, along with healthcare utilization and related costs over time in adults (>18 years), children and adolescents (<18 years), and transitional ADHD patients (16 ≤ 24 years).
METHODS: Using anonymized German claims data (InGef), patients with ADHD diagnosis codes (ICD-10GM F90.0) between 2017 and 2023 were identified. Administrative prevalence and incidence (absence of ADHD diagnosis 12 months prior) were calculated annually. Healthcare resource utilization (HCRU) and costs were evaluated for each year of observation.
RESULTS: A total of 78,919 ADHD patients were identified in 2023. In the same year administrative prevalence was 0.6% among adults, 2.7% for transitional patients and 3.6% among children and adolescents; incidence rates were 0.1%, 0.5% and 1.0%, respectively. The prevalence and incidence in adults and transitional patients have been increasing since 2017, whereas rates for children and adolescents have remained stable. Males demonstrated higher prevalence and incidence compared to females across all age groups, though the gender disparity decreases with age. Average total yearly costs for prevalent ADHD patients in 2023 were €3,527, with adults and children/adolescents incurring similar costs, while transitional patients had lower average costs of €2,912. The primary cost drivers were inpatient and outpatient care (73%), while pharmaceuticals (10%) and remedies/aids (16%) played a minor role.
CONCLUSIONS: This study highlights an increasing prevalence and incidence of ADHD among adults and transitional patients in Germany from 2017 to 2023, while rates in children and adolescents remained stable. Prevalence in adulthood is likely underestimated given an assumed persistence rate of 50%, suggesting potential underdiagnosis and underserved healthcare. Transitional patients incurred comparatively lower HCRU and costs compared to adult and children/adolescent ADHD patients and may require increased attention.
METHODS: Using anonymized German claims data (InGef), patients with ADHD diagnosis codes (ICD-10GM F90.0) between 2017 and 2023 were identified. Administrative prevalence and incidence (absence of ADHD diagnosis 12 months prior) were calculated annually. Healthcare resource utilization (HCRU) and costs were evaluated for each year of observation.
RESULTS: A total of 78,919 ADHD patients were identified in 2023. In the same year administrative prevalence was 0.6% among adults, 2.7% for transitional patients and 3.6% among children and adolescents; incidence rates were 0.1%, 0.5% and 1.0%, respectively. The prevalence and incidence in adults and transitional patients have been increasing since 2017, whereas rates for children and adolescents have remained stable. Males demonstrated higher prevalence and incidence compared to females across all age groups, though the gender disparity decreases with age. Average total yearly costs for prevalent ADHD patients in 2023 were €3,527, with adults and children/adolescents incurring similar costs, while transitional patients had lower average costs of €2,912. The primary cost drivers were inpatient and outpatient care (73%), while pharmaceuticals (10%) and remedies/aids (16%) played a minor role.
CONCLUSIONS: This study highlights an increasing prevalence and incidence of ADHD among adults and transitional patients in Germany from 2017 to 2023, while rates in children and adolescents remained stable. Prevalence in adulthood is likely underestimated given an assumed persistence rate of 50%, suggesting potential underdiagnosis and underserved healthcare. Transitional patients incurred comparatively lower HCRU and costs compared to adult and children/adolescent ADHD patients and may require increased attention.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH118
Topic
Economic Evaluation, Epidemiology & Public Health, Health Service Delivery & Process of Care
Disease
Neurological Disorders